Integumen PLC (LON:SKIN) CEO Gerry Brandon speaks to Proactive London’s Andrew Scott soon after announcing the roll-out of a new Labskin test designed to clone the skin of volunteers in clinical trials.
He says the new test will cut the number of volunteers required for trials by 50%, reduce recruitment times and project management costs as well as make them more reliable and accurate.
Source Link www.proactiveinvestors.co.uk/companies
Article originally published by proactive investors. Share Talk is not responsible for its content or accuracy and may not share the author’s views. News and research are not personal recommendations to deal. All investments can fall in value so you could get back less than you invest.
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned